These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3428127)

  • 1. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.
    Zanetti S; Ungheri D; Castellani Pastoris M; Fadda G
    Drugs Exp Clin Res; 1987; 13(10):631-4. PubMed ID: 3428127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
    Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
    Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis.
    Zanetti S; Usai D; Nonis A; Fadda G
    J Antimicrob Chemother; 1996 Feb; 37(2):357-9. PubMed ID: 8707747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.
    Jones RB; Ridgway GL; Boulding S; Hunley KL
    Rev Infect Dis; 1983; 5 Suppl 3():S556-61. PubMed ID: 6635445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
    Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.
    Treharne JD; Yearsley PJ; Ballard RC
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1393-4. PubMed ID: 2552911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
    Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.
    Prasad ES; Wenman WM
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):135-6. PubMed ID: 8467625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative in vitro activities of rifabutin and rifampicin against various mycobacteria using 7H10 agar and 1% Ogawa egg media].
    Sato K; Saito H; Tomioka H
    Kekkaku; 1988 Sep; 63(9):601-4. PubMed ID: 2854588
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative in vitro activity of a new macrolide RU 28965 and of erythromycin against Chlamydia trachomatis].
    Dutilh B; de Barbeyrac B; Lafferrière C; Bébéar C
    Pathol Biol (Paris); 1986 May; 34(5):445-7. PubMed ID: 3534718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria.
    Lamanna A; Orsi A
    Chemioterapia; 1984 Dec; 3(6):365-7. PubMed ID: 6529778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ciprofloxacin against Chlamydia trachomatis and Ureaplasma urealyticum.
    Rumpianesi F; Sambri V; Bertini S; Tamba I; Cevenini R
    Chemioterapia; 1984 Jun; 3(3):173-4. PubMed ID: 6529772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae.
    Rothstein DM; Suchland RJ; Xia M; Murphy CK; Stamm WE
    J Antibiot (Tokyo); 2008 Aug; 61(8):489-95. PubMed ID: 18997387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.
    Wang SA; Papp JR; Stamm WE; Peeling RW; Martin DH; Holmes KK
    J Infect Dis; 2005 Mar; 191(6):917-23. PubMed ID: 15717267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of in vitro activity of ofloxacin against 73 strains of Chlamydia trachomatis isolated from gynecologic infections].
    Catalan F; Milovanovic A; Prouteau C; Soulignac M
    Pathol Biol (Paris); 1998 Feb; 46(2):144-6. PubMed ID: 9769927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM
    Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic susceptibility testing for Chlamydia trachomatis using flow cytometry.
    Dessus-Babus S; Belloc F; Bébéar CM; Poutiers F; Lacombe F; Bébéar C; de Barbeyrac B
    Cytometry; 1998 Jan; 31(1):37-44. PubMed ID: 9450523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
    Garey KW; Salazar M; Shah D; Rodrigue R; DuPont HL
    Ann Pharmacother; 2008 Jun; 42(6):827-35. PubMed ID: 18430792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of intracellular multiplication of human strains of Chlamydia trachomatis by nitric oxide.
    Igietseme JU; Uriri IM; Chow M; Abe E; Rank RG
    Biochem Biophys Res Commun; 1997 Mar; 232(3):595-601. PubMed ID: 9126319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.